Aeovian Pharmaceuticals

📍 Berkeley, United States👥 11 employees💰 Last funded Dec 2025
Biotechnology Research🌐 aeovian.com
Website LinkedIn
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Our lead development candidate, AV078, is a first-in-class CNS-penetrant selective mTORC1 inhibitor in Phase 2 development for refractory epilepsy associated with tuberous sclerosis complex (TSC), a rare genetic disorder driven by hyperactive mTORC1 signaling. Beyond AV078, we’ve developed a proprietary library of small molecules, which are potent and selective mTORC1 and CD38 inhibitors that have the potential to precisely target the underlying biology of multiple rare and age-related disease.
4
Total investors
0
Early stage
0
Mid stage
2
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
2
Germany
1
Canada
1
Investor activity2019–2025 · investors recorded per year
201922023120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Aeovian Pharmaceuticals?
Aeovian Pharmaceuticals has 4 investors on record on gritt.io and 2 late-stage investors.
When did Aeovian Pharmaceuticals last raise funding?
The most recent investment in Aeovian Pharmaceuticals recorded on gritt.io was in December 2025.
What industry is Aeovian Pharmaceuticals in?
Aeovian Pharmaceuticals operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Aeovian Pharmaceuticals based?
Aeovian Pharmaceuticals is headquartered in Berkeley, United States.